<html>
<head>
<title>As researchers pursue links between bacteria and human health, startups stand to benefit • TechCrunch</title>
<link href="../Styles/Style.css" type="text/css" rel="stylesheet"/>
</head>
<body>
<h1 class="translated">随着研究人员探索细菌与人类健康之间的联系，初创公司将受益于 TechCrunch</h1>
<blockquote>原文：<a href="https://web.archive.org/web/https://techcrunch.com/2019/04/17/as-researchers-pursue-links-between-the-microbiome-and-human-health-startups-reap-the-rewards/">https://web.archive.org/web/https://techcrunch.com/2019/04/17/as-researchers-pursue-links-between-the-microbiome-and-human-health-startups-reap-the-rewards/</a></blockquote><div><div class="article-content">
				<p id="speakable-summary" class="translated">2009 年，美国国立卫生研究院启动了一个为期五年、耗资 1.5 亿美元的项目，旨在刺激对一个新医学领域的研究，该领域旨在检查人体肠道中数百万种细菌与整体人类健康之间的联系。</p>
<p class="translated">在 10 年前遗传学进步的推动下，这一新的研究领域将不仅绘制人类基因组图，还绘制体内微生物的基因序列图，以确定它们的功能以及在确保人类健康方面发挥的作用。</p>
<p class="translated">十年后，投资者正在鼓励这些工具的商业化，为初创公司提供了数亿美元的融资，这些公司的名字类似于<a href="https://web.archive.org/web/20221203131542/https://ubiome.com/"> uBiome </a>、<a href="https://web.archive.org/web/20221203131542/https://www.viome.com/"> Viome </a>、<a href="https://web.archive.org/web/20221203131542/https://finchtherapeutics.com/">Finch therapies</a>、<a href="https://web.archive.org/web/20221203131542/https://www.kallyope.com/"> Kallyope </a>、<a href="https://web.archive.org/web/20221203131542/https://www.secondgenome.com/">第二基因组</a>、<a href="https://web.archive.org/web/20221203131542/https://www.humanlongevity.com/">人类寿命</a>、<a href="https://web.archive.org/web/20221203131542/https://www.maatpharma.com/">玛特制药</a>、<a href="https://web.archive.org/web/20221203131542/https://seed.com/"> Seed </a>等等。</p>
<p class="translated">总的来说，这些公司已经筹集了超过 5 亿美元。</p>
<p class="translated">其中一些公司，如芬奇治疗公司、第二基因组公司和玛特制药公司，完全属于大型制药公司的临床领域——通过标准研究技术和临床试验开发疾病治疗方法。</p>
<p class="translated">其他的，如 uBiome 和 Viome，则是直接面向消费者的。希望通过消费者微生物群分析套件积累关于微生物群的大量知识，为客户提供肠道微生物群的快照，并就饮食改变如何改善他们的整体健康提供基本建议。</p>
<p/><div id="attachment_1813973" class="wp-caption alignnone"><img aria-describedby="caption-attachment-1813973" decoding="async" loading="lazy" class="size-full wp-image-1813973" src="../Images/64d2900fe41445627a37a32898b0f481.png" alt="" srcset="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png 2644w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=150,75 150w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=300,150 300w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=768,383 768w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=680,339 680w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=1536,767 1536w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=2048,1022 2048w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=1200,599 1200w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png?resize=50,25 50w" sizes="(max-width: 1024px) 100vw, 1024px" data-original-src="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2019/04/Screen-Shot-2019-04-17-at-9.43.03-AM.png"/><p id="caption-attachment-1813973" class="wp-caption-text translated">Viome 首席执行官兼联合创始人 Naveen Jain</p></div>
<p class="translated">这些公司在管理补充剂和营养药物的监管灰色地带运营，这意味着它们不需要获得监管批准。</p>
<p class="translated">但是，随着他们寻求在零售店和科学期刊中获得验证和认可，他们开始关注经过临床验证的试验，以证明他们建议背后的科学是合理的，从而使他们能够在药物开发的价值链中更上一层楼。这就像是 23andMe 用来收集大量基因知识的策略，该公司现在正在向药物公司提供这些知识，以便他们可以合作开发新的疾病治疗方法。</p>
<p class="translated">今年早些时候，uBiome 自 2012 年推出以来，已经从投资者那里筹集了超过 1 亿美元的微生物组测试套件，<a href="https://web.archive.org/web/20221203131542/https://www.cnbc.com/2019/01/22/ubiome-job-cuts-more-than-50.html">解雇了 50 多名员工</a>，该公司表示，此举旨在重新专注于药物开发。</p>
<p class="translated">现在，Viome 已经筹集了 2500 万美元，它正在进行大约 15 项临床研究试验，并寻求开发自己的治疗方法。</p>
<p class="translated">Jain 说，试验的目标是“表明我们推荐的干预措施确实产生了效果”。</p>
<p class="translated"><a href="https://web.archive.org/web/20221203131542/https://www.sciencedirect.com/science/article/pii/S0014299918303595#!">最近的科学研究</a>表明，关注微生物群健康可以减轻疾病负担或减缓多种疾病的进展，包括<a href="https://web.archive.org/web/20221203131542/https://www.sciencedirect.com/science/article/pii/S0014299918303595#bib123">抑郁症</a>、<a href="https://web.archive.org/web/20221203131542/https://www.sciencedirect.com/science/article/pii/S0014299918303595#bib151">骨关节炎</a>、<a href="https://web.archive.org/web/20221203131542/https://www.sciencedirect.com/science/article/pii/S0014299918303595#bib189">功能性肠病</a>和<a href="https://web.archive.org/web/20221203131542/https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/multiple-sclerosis">多发性硬化症</a>。</p>
<p/><div id="attachment_1625147" class="wp-caption alignnone"><img aria-describedby="caption-attachment-1625147" decoding="async" loading="lazy" class="size-full wp-image-1625147" src="../Images/d86919bb378e1db8f477bd7177a79627.png" alt="" srcset="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg 2750w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=150,111 150w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=300,221 300w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=768,567 768w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=680,502 680w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=1536,1133 1536w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=2048,1511 2048w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=1200,885 1200w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg?resize=50,37 50w" sizes="(max-width: 1024px) 100vw, 1024px" data-original-src="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2018/04/gettyimages-713768587.jpg"/><p id="caption-attachment-1625147" class="wp-caption-text translated">图片来源:安德鲁·布鲁克斯/盖蒂图片社</p></div>
<p class="translated">Viome 则专注于结肠直肠癌、乳腺癌、抑郁症和焦虑症、糖尿病和肥胖症、克罗恩病、结肠炎和消化系统疾病。</p>
<p class="translated">虽然 Viome 在申请专利和发表论文方面落后于其他公司，但来自新老投资者的 2500 万美元资金可能会改变这一局面，这些投资者包括 Khosla Ventures、Bold Capital、Marc Benioff、Physician Partners、Hambrecht health care Growth Venture Fund 和 Global Infrastructure Partners 的 Matthew Harris。</p>
<p class="translated">Jain 表示，Viome 在直接面向消费者的微生物领域与其他公司的区别在于其测试技术。该公司是 Jain 的 BlueDot venture 的第一个分支，该公司的成立是为了将来自全国各个国家研究实验室的孤立技术商业化。</p>
<p class="translated">Viome 的测试源于蓝点从洛斯阿拉莫斯国家实验室(Los Alamos National Laboratory)获得的技术，这是核糖核酸测序的一种变体，这种信使机制向细胞提供它们应该产生什么的指令。</p>
<p class="translated">Jain 和他的科学家团队认为，通过对 RNA 进行测序，他们可以看到细菌如何在体内产生有益或有害人类健康的化学物质的信号通路和代谢通路。</p>
<p class="translated">Viome 和 uBiome 都受益于他们对“量化自我”、“生物黑客”和健康社区的支持，这些社区正在寻找使用顺势疗法或自然疗法治疗许多疾病的方法来优化健康。</p>
<p/><div id="attachment_1228418" class="wp-caption alignnone"><img aria-describedby="caption-attachment-1228418" decoding="async" loading="lazy" class="wp-image-1228418 size-full" src="../Images/5c59cc8d967301456b98ce8d953baa31.png" alt="" srcset="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg 1000w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg?resize=150,100 150w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg?resize=300,200 300w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg?resize=768,512 768w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg?resize=680,454 680w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg?resize=50,33 50w" sizes="(max-width: 1000px) 100vw, 1000px" data-original-src="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2015/10/shutterstock_248898337.jpg"/><p id="caption-attachment-1228418" class="wp-caption-text translated">图片由 Shutterstock 提供</p></div>
<p class="translated">“三年前，微生物群是一个非常小众的市场，现在这个市场更加主流。“既然它是主流，它就必须为人们服务，”贾恩说。“它不能简单地成为自我量化者的研究工具。它必须传递价值。”</p>
<p class="translated">这就是该公司开始开发临床试验的原因——贾恩说，这个过程伴随着一些成长的烦恼。</p>
<p class="translated">简单浏览一下消费者报告网站上对<a href="https://web.archive.org/web/20221203131542/https://dnatestingchoice.com/en-us/microbiome-testing/provider/viome/5298">公司产品的顾客评论，就会发现并非所有人都接受 Viome 的产品和服务，Jain 将这些评论归因于该公司获得 CLIA 认证的决定——Jain 说这是进行临床试验研究所必需的。</a></p>
<p class="translated">“去年 11 月和 12 月，我们经历了成长的烦恼。我们发展很快，我们希望成为临床认证实验室…杰恩说:“我们获得联邦认证后，认证花了一个月的时间，我们需要获得州认证。”。"在那三个月里，我们接待了许多不满意的顾客。"</p>
<p class="translated">一些行业观察人士认为，专注于微生物组的初创公司的困境与其说是因为它们进入了临床试验，不如说是因为这些公司过早进入了市场，而许多科学知识仍未得到证实。</p>
<p class="translated">“T <span>他微生物群落空间也非常重要。但在科学方面，仍有大量信息有待发现，对这些数据的收集和理解需要推动该领域的发展，”消费者健康市场的一位企业家表示。“但对消费者来说，这个过程还为时过早。”</span></p>
<p class="translated">这可能是 Viome 和 uBiome 都在寻求开发治疗方法的一个原因。</p>
<p/><div id="attachment_1371012" class="wp-caption alignnone"><img aria-describedby="caption-attachment-1371012" decoding="async" loading="lazy" class="wp-image-1371012 size-full" src="../Images/63ca6ebcbe543d08d1b67cda7aba46ef.png" alt="" srcset="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg 2161w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=150,96 150w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=300,193 300w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=768,493 768w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=680,436 680w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=1536,986 1536w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=2048,1314 2048w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=1200,770 1200w, https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg?resize=50,32 50w" sizes="(max-width: 1024px) 100vw, 1024px" data-original-src="https://web.archive.org/web/20221203131542im_/https://techcrunch.com/wp-content/uploads/2016/08/gettyimages-184111081.jpg"/><p id="caption-attachment-1371012" class="wp-caption-text translated">照片由盖蒂图片社提供</p></div>
<p class="translated">Jain 说:“我们将在出售这些套件上达到收支平衡或赔钱。“一旦我们理解了人们为什么会失眠、糖尿病和抑郁，那么我们就可以提出一套每个人需要的个性化营养物质……有些可能是新型益生菌或益生元。”</p>
<p class="translated">与此同时，uBiome <a href="https://web.archive.org/web/20221203131542/https://www.prweb.com/releases/peer_reviewed_paper_in_frontiers_in_bioengineering_and_biotechnology_reveals_that_ubiome_has_the_largest_patent_portfolio_in_the_microbiome_space/prweb16169495.htm">正在吹捧自己的专利组合</a>，称之为其服务背后的真正科学(尽管大多数专利都是围绕其用于排序和分析微生物群健康的技术，而不是基于其分析的任何治疗方案)。</p>
<p class="responsiveNews translated">就投资组合规模而言，该公司的首席执行官和研究人员分别位居第一、第二和第三，就专利质量而言，他们分别位居第二、第三和第四。根据 uBiome 上个月的一份声明，这项研究提供了一个案例，说明深入的专利分析如何从大型专利数据库中识别技术和投资趋势的早期指标。</p>
<p class="responsiveNews translated">该公司表示，这些专利涵盖了他们的微生物组测试试剂盒的方法和分析，以及心血管疾病、内分泌疾病、自身免疫性疾病、神经系统疾病等疾病的诊断和治疗。</p>
<p class="translated">Jain 和 uBiome 首席执行官 Jessica Richman 都不太可能成为微生物治疗潜力的旗手。两人都没有科学背景，但都坚信有必要让消费者快速获得科学的潜在好处。</p>
<p class="translated">“美国国立卫生研究院资助的人类微生物组项目(HMP)是一项为期五年、耗资 1.73 亿美元的努力，旨在更好地了解人类微生物组，从 2007 年持续到 2012 年 8 月。我们于 2012 年 11 月在 Indiegogo 上开始了我们的众筹活动——就在它结束之后，”Richman 在 Y Combinator 网站上发表的一次采访中说道。“我们希望将 HMP 的结果直接带给公众，让我们所有人都能尽快了解我们的微生物组并参与科学——而不是年复一年地等待结果渗透到人们可以使用的产品和服务中。”</p>
<p class="translated">对于贾恩来说，Viome 代表着一个回报社会的机会，也是一个为杀死他父亲的疾病找到治疗方法的机会。</p>
<p class="translated">贾恩说:“对我来说，这不仅仅是一家公司，这是我的一项使命，这是我对父亲的承诺，要把事情做好。“这也是向前支付的一部分。”</p>
			</div>

			</div>    
</body>
</html>